Rising Hypertension Fuels Growth In Acute Ischemic Stroke Therapeutics Market: A Key Factor Shaping the Future of the Acute Ischemic Stroke Therapeutics Market in 2025

Get 20% OFF on all 2025 Global Market Reports until March 31st! Apply code FY25SAVE and grab your savings today!

What combination of drivers is leading to accelerated growth in the acute ischemic stroke therapeutics market?
The anticipated increase in hypertension is predicted to fuel the expansion of the acute ischemic stroke therapeutics market. Hypertension, also known as high blood pressure, is a health condition characterized by a continual increase in the pressure of blood on the artery walls, heightening the likelihood of cardiac disease, stroke, and other associated health issues. The growing incidence of hypertension is chiefly attributed to an aging populace and a surge in obesity rates. Acute ischemic stroke therapeutics work to control escalating hypertension by tackling stroke-derived issues and averting additional cerebrovascular harm, frequently associated with high blood pressure. For example, as per the National Health Service England, a government agency based in the UK, approximately 30% of US adults were dealing with hypertension in May 2023, with 15% having hypertension that's not been treated. Furthermore, the frequency of hypertension rose with age, fluctuating from 9% in adults between 16 to 44 years old to 60% in those aged 65 and above. Consequently, the escalating rates of hypertension are stimulating the growth of the acute ischemic stroke therapeutics market.

Get Your Acute Ischemic Stroke Therapeutics Market Report Here:
https://www.thebusinessresearchcompany.com/report/acute-ischemic-stroke-therapeutics-global-market-report

What is the projected compound annual growth rate (CAGR) of the acute ischemic stroke therapeutics market from 2025 to 2034, and what factors influence it?
In recent times, there has been a robust growth in the market size for therapeutics for acute ischemic stroke. The projections show an increase from $9.24 billion in 2024 to $10.12 billion in 2025, indicating a Compound Annual Growth Rate (CAGR) of 9.5%. Factors contributing to this growth during the historic period include increased patient count, a surge in aging population, elevated obesity rates, a heightened incidence of ischemic stroke, and a rise in hypertension cases.

The market size for acute ischemic stroke therapeutics is projected to experience robust growth in the coming years. The forecast predicts a rise to $14.38 billion by 2029, with a compound annual growth rate (CAGR) of 9.2%. Factors contributing to this growth during the forecast period include a rising preference for online pharmacies, an increase in cardiovascular diseases, escalating cholesterol levels, an increased disease prevalence, and a growing incidence of ischemic stroke. Key trends for the forecast period include medical technology advancements, the incorporation of artificial intelligence and machine learning, advancements in neurology, and the embracement of advanced technological diagnostics.

Get Your Free Sample Now - Explore Exclusive Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=19265&type=smp

How are the latest trends influencing the growth of the acute ischemic stroke therapeutics market?
Major players in the acute ischemic stroke therapeutics market are prioritizing the development of state-of-the-art medical technologies via groundbreaking methodologies, such as exosome-based therapy for neurological indications. This innovative approach boosts the efficiency of the treatments and enhances patient outcomes. Central to this strategy is the use of exosomes - minuscule extracellular particles (30-150 nm in size) released by cells that take part in cellular communication. For example, Aruna Bio, a neural exosome platforms' developer based in the US, in January 2024, got the approval from the Food and Drug Administration (FDA) for the investigational new drug application for AB126. This marked the first exosome-based therapy to undergo human clinical trials for a neurological indication, specifically acute ischemic stroke. The Phase 1b/2a clinical trial is scheduled to commence in early 2024, concentrating on the safety, tolerability, and preliminary effectiveness of AB126 in post-thrombectomy patients with a grim outlook. AB126, culled from unique neural stem cells, can permeate the blood-brain barrier and demonstrated anti-inflammatory and neuroprotective impacts in preclinical studies.

What are the major segments of the acute ischemic stroke therapeutics market and their role in driving growth?
The acute ischemic stroke therapeuticsmarket covered in this report is segmented -

1) By Type: Thrombolytic Therapeutics, Antihypertensive Therapeutics, Antiplatelet Therapeutics, Anticoagulants
2) By Route Of Administration: Oral, Parenteral
3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
4) By Application: Hospitals, Ambulatory Surgical Center, Diagnostic Centers

Subsegments:
1) By Thrombolytic Therapeutics: Tissue Plasminogen Activators (tPA), Urokinase
2) By Antihypertensive Therapeutics: Angiotensin-Converting Enzyme (ACE) Inhibitors, Angiotensin II Receptor Blockers (ARBs), Beta Blockers, Calcium Channel Blockers, Diuretics
3) By Antiplatelet Therapeutics: Aspirin, Clopidogrel, Ticagrelor, Dipyridamole, Cilostazol
4) By Anticoagulants: Vitamin K Antagonists, Direct Oral Anticoagulants (DOACs), Heparins

Unlock Exclusive Market Insights - Purchase Your Research Report Now!
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=19265

Which regions are key players in the growth of the acute ischemic stroke therapeutics market?
North America was the largest region in the acute ischemic stroke therapeutics market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the acute ischemic stroke therapeutics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Who are the key firms paving the way for growth in the acute ischemic stroke therapeutics market?
Major companies operating in the acute ischemic stroke therapeutics market are Johnson & Johnson, Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca PLC, Abbott Laboratories, GlaxoSmithKline plc, F. Hoffmann-La Roche Ltd., Medtronic plc, Eli Lilly and Company, Amgen Inc., Stryker Corporation, Teva Pharmaceutical Industries Limited, Merck & Co. Inc., Otsuka Pharmaceutical Co. Ltd., Biogen Inc., Daiichi Sankyo Company Limited, Eisai Co. Ltd., Genentech Inc., NoNO Inc., Athersys Inc., XBiotech Inc., ZZ Biotech LLC

Customize Your Report - Get Tailored Market Insights!
https://www.thebusinessresearchcompany.com/sample.aspx?id=19265&type=smp

What Is Covered In The Acute Ischemic Stroke Therapeutics Global Market Report?

•Market Size Forecast: Examine the acute ischemic stroke therapeutics market size across key regions, countries, product categories, and applications.
•Segmentation Insights: Identify and classify subsegments within the acute ischemic stroke therapeutics market for a structured understanding.
•Key Players Overview: Analyze major players in the acute ischemic stroke therapeutics market, including their market value, share, and competitive positioning.
•Growth Trends Exploration: Assess individual growth patterns and future opportunities in the acute ischemic stroke therapeutics market.
•Segment Contributions: Evaluate how different segments drive overall growth in the acute ischemic stroke therapeutics market.
•Growth Factors: Highlight key drivers and opportunities influencing the expansion of the acute ischemic stroke therapeutics market.
•Industry Challenges: Identify potential risks and obstacles affecting the acute ischemic stroke therapeutics market.
•Competitive Landscape: Review strategic developments in the acute ischemic stroke therapeutics market, including expansions, agreements, and new product launches.

Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ"

Learn More About The Business Research Company
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.

Our flagship product, the Global Market Model (GMM), is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.